Latest Intellectual Property News

dorsaVi has secured significant commercial and clinical milestones with new elite sports and European clinical partnerships, showcasing its advanced real-time AI sensor technology.

Neurizon Therapeutics announces the resignation of CEO Dr Michael Thurn, with Executive Chair Sergio Duchini stepping in temporarily as the company embarks on a global hunt for new leadership.

EVE Health Group has raised $0.9 million to advance its pharmaceutical reformulation programs targeting global markets worth over US$30 billion. The funding will support development of improved delivery technologies for medicines nearing patent expiry.

RLF AgTech has completed its restructuring phase and is now shifting gears towards aggressive commercial execution under new CEO Stuart Upton. The company outlined its growth strategy and financial results in a recent investor webinar, signalling a clear path to profitability.

Island Pharmaceuticals has partnered with the Burnet Institute to explore new antiviral applications for its lead drugs, targeting measles, chikungunya, and Ross River virus. This collaboration leverages existing data and government funding to enhance the company’s clinical pipeline without major capital outlay.

Cobalt Blue Holdings has confirmed its cobalt sulphate meets stringent battery precursor specifications, advancing its Kwinana Cobalt Refinery toward a Final Investment Decision. The company also expands its graphite recovery program, positioning itself at the forefront of Australia’s battery materials ecosystem.

Opthea Limited reports a striking turnaround with a $339.9 million profit for H1 2026, driven by a strategic refocus on developing OPT-302 for Lymphangioleiomyomatosis (LAM), a rare lung disease affecting women. The company plans a rebrand and ASX reinstatement as it charts a new course in rare respiratory health.

MCS Services Limited has reported a significantly reduced half-year loss and announced plans to sell its Highways Traffic subsidiary, aiming to strengthen its financial position amid ongoing challenges.

Yojee Limited reported a 9% revenue increase driven by software activities, while net losses widened due to accelerated investment in its MOSAIC platform and joint venture costs. The company maintains a robust cash balance and has strengthened its leadership ahead of a mid-2026 commercial launch.

ClearVue Technologies reported a 9% reduced half-year loss of $5.25 million, while pushing forward with significant advancements in its solar glass technology and expanding global licensing partnerships.

Argent BioPharma reported a significantly reduced half-year loss of A$2.9 million, progressing a strategic acquisition to bolster its CannEpil drug pipeline and securing up to A$11 million in new funding.

Recce Pharmaceuticals reported a doubling of its net loss for the half-year ended December 2025 amid significant progress in its anti-infective drug development and a substantial funding boost. The company is advancing Phase 3 trials and expanding its patent portfolio while managing financial pressures.